Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974218 | 0.85 | RAB9A (0.44) | L3MBTL1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL2966501 | 0.80 | APAF1 (0.39) | SMN1; SMN2HTTMAPTALDH1A1CYP2C19 | |
| SCHEMBL202338 | 0.80 | ALDH1A1 (0.47) | L3MBTL1SMN1; SMN2HTTNISCHKMT2A | |
| SCHEMBL2701360 | 0.80 | HDAC1 (0.36) | L3MBTL1SMN1; SMN2HTTNISCHPDE3B | |
| SCHEMBL202639 | 0.78 | MAPT (0.46) | MAPTCA1CA2CA7CA9 | |
| SCHEMBL10518939 | 0.76 | PDE3B (0.48) | L3MBTL1SMN1; SMN2HTTNISCHPDE3B | |
| SCHEMBL2701148 | 0.75 | ABL1 (0.34) | L3MBTL1SMN1; SMN2HTTNISCHMAPT | |
| SCHEMBL201907 | 0.75 | PLA2G7 (0.42) | CYP2C19 | |
| SCHEMBL202371 | 0.75 | AR (0.49) | SMN1; SMN2HTTALDH1A1CYP2C19CYP3A4 | |
| SCHEMBL2981282 | 0.72 | MEN1 (0.46) | L3MBTL1SMN1; SMN2HTTNISCHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104803916-A | Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV | 2015-07-29 | — | — | CN | claimed |
| EP-1817292-B1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-08 | — | — | EP | claimed |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2010-10-21 | — | — | US | claimed |
| US-7781473-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) | J & J Pharmaceutical Research & Development, LLC. (US) | 2010-08-24 | — | — | US | claimed |
| US-7465809-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-16 | — | — | US | claimed |
| EP-1817292-A2 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-15 | — | — | EP | claimed |
| US-20060211756-A1 | Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | claimed |
| WO-2006055184-A2 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-26 | — | — | WO | claimed |
| CN-104803916-B | Hete rocyclic derivatives as SARM (SARMS) | 詹森药业有限公司 | 2017-08-11 | — | — | CN | disclosed |
| CN-104803916-A | Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV | 2015-07-29 | — | — | CN | disclosed |
| EP-1817292-B1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-08 | — | — | EP | disclosed |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2010-10-21 | — | — | US | disclosed |
| US-7781473-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) | J & J Pharmaceutical Research & Development, LLC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100160330-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ZHANG XUQING | 2010-06-24 | — | — | US | disclosed |
| EP-1991549-A1 | BICYCLIC IMIDAZOLE OR THIADIAZOLE HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-11-19 | — | — | EP | disclosed |
| US-20070197521-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
| WO-2007095423-A1 | BICYCLIC IMIDAZOLE OR THIADIAZOLE HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | WO | disclosed |
| EP-1817292-A2 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20060211756-A1 | Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| WO-2006055184-A2 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160330-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, FSHR | L3MBTL1 4722/4885SMN1; SMN2 4566/4885HTT 2868/4885 |
| US-20060211756-A1 | Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | AR, NR5A1, NR5A2 | L3MBTL1 4796/4885SMN1; SMN2 4074/4885HTT 2508/4885 |
| US-20070197521-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, FSHR | L3MBTL1 4722/4885SMN1; SMN2 4566/4885HTT 2868/4885 |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | L3MBTL1 4796/4885SMN1; SMN2 4074/4885HTT 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.